News

The company will use the investment to fund the progression of its acute kidney disease therapy through Phase II clinical trials over the next three years. Funds will

Tony Holler, Inviro chairman of the board and former CEO of ID Biomedical, will serve as the company’s interim CEO until a permanent replacement is named. Mr Clarke

Dr Carter joins VLST from Seattle Genetics, where he led antibody technologies since 2003 including as vice president, since 2004. Prior to that, Dr Carter was director of

Piramal Healthcare will pay cash consideration of E7.7 million for the transaction. The transaction includes the brand rights, contracts, registrations, dossiers and know-how relating to Haemaccel and associated

FDC’s Ciprofloxacin Ophthalmic Solution is a broad spectrum antibiotic used for occular surface infections. The company has recently received approval for Timolol maleate ophthalmic solution. Another abbreviated new

The acquisition was completed by way of an asset purchase under which Natus acquired the assets of the neurology division of Schwarzer including all shares in MMT Muenchner

The negotiated contract is valued at approximately $359,000 per year for a total of approximately $1.8 million over the life of the contract. After the initial one year

The new patent is related to treatment of patients in need of bone marrow or stem cell transplantation. This patent is based on evidence that treatment with SDF-1

The Phase IIb trial was designed to explore the safety, tolerability and efficacy of Spheramine, the company’s novel cell-based therapy for the potential treatment of moderate to advanced